NanoString Technologies Inc. Announces Publication In The Journal Of Clinical Oncology Showing The Prosigna Assay Identifies Women With A Low Risk Of Late Distant Recurrence Of Breast Cancer

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that the Journal of Clinical Oncology published an analysis of data in over 2,100 patients showing that the risk-of-recurrence (ROR) score generated by the PAM50-based Prosigna™ Breast Cancer Assay predicts the risk of late distant recurrence, after five years of endocrine therapy, in postmenopausal women with Hormone Receptor-Positive (HR+) early-stage breast cancer. These results, in combination with previously published clinical studies, demonstrate the potential for Prosigna to inform both the use of adjuvant chemotherapy and the use of extended adjuvant endocrine therapy based on a single risk score.

Help employers find you! Check out all the jobs and post your resume.

Back to news